Lovenox Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Impact of low molecular weight heparin (LMWH) on SARS-CoV2 Infection: HEPARIN SARS-CoV2 clinical trial.
Conclusions: No differences were found in the evolution of COVID between the two treatment groups for the profile of patients included in the trial. The increase in LMWH at an intermediate dose does not contribute benefits in a profile of patients with COVID who required hospitalization, but who had a favorable evolution in most of them. Financing: SEPAR 1128 and Neumosur Foundation. Enoxaparin 40mg/sc/day n(%) Enoxaparin 1 mg/Kg/day n(%) Mortality01(2)Oxigen therapy escalation21(37)17(31)Invasive mechanical ventilation1 (2)1 (2)Need for rescue medication17 (30)13 (24)Length of hospitalization; days median (IQR)7 (7)7 (7)...
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Otero Candelera, R., Gonzalez-Vergara, D., Caparros, I., Garcia-Ortega, A., Rodriguez-Matute, C., Moises, J., Marin-Barrera, L., Rodriguez-Martorell, J. Tags: Respiratory infections and bronchiectasis Source Type: research

Anti-factor Xa level monitoring of low-molecular-weight heparin for prevention of venous thromboembolism in critically ill patients (AXaLPE): protocol of a randomised, open-label controlled clinical trial
This study is a randomised controlled trial to investigate the effect of aFXa level monitoring on reducing VTE and to establish a new method for accurately preventing VTE in critically ill patients with low-molecular-weight heparin (LMWH). Methods and analysis A randomised controlled trial is planned in two centres with a planned sample size of 858 participants. Participants will be randomly assigned to three groups receiving LMWH prophylaxis at a 1:1:1 ratio: in group A, peak aFXa levels will serve as the guide for the LMWH dose; in group B, the trough aFXa levels will serve as the guide for the LMWH dose; and in group C...
Source: BMJ Open - October 25, 2023 Category: General Medicine Authors: Wang, C., Ning, Y.-c., Song, L.-p., Li, P.-j., Wang, F.-h., Ding, M.-x., Jiang, L., Wang, M., Pei, Q.-Q., Hu, S.-m., Wang, H. Tags: Open access, Intensive care Source Type: research

Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19
Randomized clinical trials in non-critically ill COVID-19 patients showed that therapeutic-dose heparin increased survival with reduced organ support as compared with usual-care thromboprophylaxis, albeit with... (Source: BMC Infectious Diseases)
Source: BMC Infectious Diseases - October 24, 2023 Category: Infectious Diseases Authors: B. Cosmi, M. Giannella, G. Fornaro, F. Cristini, A. Patacca, A. Castagna, F. Mazzaferri, S. Testa, A. Pan, M. Lupi, P. Brambilla, A. Montineri, S. Frattima, E. G. Bignami, M. Salvetti, G. De Stefano & hellip; Tags: Research Source Type: research

A rare complication of IgA vasculitis: renal and intestinal ischemia successfully treated with plasmapheresis
CONCLUSIONS: Plasmapheresis seems to be an effective treatment option in IgAV-related ischemic findings that do not respond to intensive immunosuppressive therapy.PMID:37853978 | DOI:10.24953/turkjped.2022.935 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - October 19, 2023 Category: Pediatrics Authors: Şeyma Türkmen Sevin ç Taşar Meryem G üzel Hafize Emine S önmez Mustafa Çakan Bet ül Sözeri Source Type: research